Sepsis Therapeutics

Global Market Trajectory & Analytics

MCP-6525

EXECUTIVE ENGAGEMENTS

* Login for a full stack data experience

DATE

APR 2021

TABLES

18

72

EDITION

18

PRICE

USD 5600

CODE

MCP-6525

*Engagement stats are ongoing and dynamic

COMPETITIVE METRICS

COMPANY	D S N T	% *
Adrenomed AG		Login Required
AMOMED Pharma GmbH		Login Required
AM-Pharma BV		Login Required
Arch Biopartners, Inc.		Login Required
Aridis Pharmaceuticals, Inc.		Login Required
Asahi Kasei Pharma America		Login Required
Astellas Pharma, Inc.		Login Required
Biocartis NV		Login Required
Biosyn Arzneimittel GmbH		Login Required
Bristol-Myers Squibb Company		Login Required

SUBMIT

* D = Dominant; S = Strong; N = Niche; T = Trivial

* Validated respondents are incentivized with cluster data

Note: Best viewed in Landscape Mode

VIEW ENTIRE POOL OF 24 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

RESEARCH MODULES MARKET TRENDS EXECUTIVES

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Sepsis Therapeutics estimated at US$14.8 Million in the year 2020, is projected to reach a revised size of US$765 Million by 2027, growing at a CAGR of 75.7% over the period 2020-2027.

The Sepsis Therapeutics market in the U.S. is estimated at US$4.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$116.6 Million by the year 2027 trailing a CAGR of 71.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 67.9% and 64.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 51.3% CAGR.

SELECT PLAYERS

Adrenomed AG; AM-Pharma B.V.; Aridis Pharmaceuticals Inc.; Asahi Kasei Pharma America; Astellas Pharma Inc.; Endacea Inc.; InflaRx GmbH; La Jolla Pharmaceutical Company; Opsonix, Inc.; T2 Biosystems Inc.; TaiRx Inc.

SEGMENTS

» Segment (Sepsis Therapeutics)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Sepsis - A Prelude

Recent Market Activity

New Treatment Protocols and New Definitions - Every Minute Counts!!

Aging Population: A Key Growth Driver for Sepsis Therapeutics

Antibiotics and Vasopressors - The Current Standard of Care

Current Categories of Antibacterial Agents for First-line Sepsis Treatment

Current Anti-bacterial Drugs used in Sepsis

Current Antifungals used for Sepsis

Current Antivirals used for Sepsis

GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment

Argipressin Gains Approval for Septic Shock in 26 EU countries

Current & Future Analysis

Growth Drivers in a Nutshell

Market Restraints

Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

Adrenomed AG (Germany)

AM-Pharma B.V. (Netherlands)

AMOMED Pharma GmbH (Austria)

Asahi Kasei Pharma America (USA)

Endacea, Inc. (USA)

InflaRx N.V. (Germany)

La Jolla Pharmaceutical Company (USA)

TaiRx, Inc. (USA)

3. MARKET TRENDS & DRIVERS

A Market Characterized by High Unmet Medical Needs

Research Activity Enables Increased Awareness of Disease Pathogenesis

Select Sepsis Therapeutics under Phase IV Clinical Trials: As of 2018

Select Sepsis Therapeutics under Phase III Clinical Trials: 2018

Novel Immune-Specific Modes of Action under Focus

Emphasizing on Endothelial Cell Function

HMGB1 - A Potential Target for Future Therapies

Nanoparticle Systems Demonstrate Potential for Use in Septic Shock Management

Researchers Employ IL-7 to Increase CD4 and CD8 Immune Cells in Patients

Hydrocortisone Displays Potential in Septic Shock Treatment

Reduced Levels of Vitamin C Characterize Sepsis Patients

Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate

Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market

Researchers Develop ss-Sepsis-3 Protocol for Evaluation of Sepsis in Animal Models

World Sepsis Day Aims to Result in Improvement in Sepsis Management

NSAIDs Demonstrate Potential to Treat Sepsis

4. GLOBAL MARKET PERSPECTIVE

World Current & Future Analysis for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES

USA Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

CANADA

Canada Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

JAPAN

Japan Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

CHINA

China Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

EUROPE

Europe Current & Future Analysis for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Europe 7-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027

FRANCE

France Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

GERMANY

Germany Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

ITALY

Italy Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

UNITED KINGDOM

UK Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

REST OF EUROPE

Rest of Europe Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

ASIA-PACIFIC

Asia-Pacific Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

REST OF WORLD

Rest of World Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

IV. COMPETITION

Total Companies Profiled: 24

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.